Topiramate in patients with epilepsy and intellectual disability

Epilepsy and Behavior

Volumn 14, Issue 3, 2009, Pages 496-502

  Martin, Peter ^a   Schreiner, Andreas ^b   Rettig, Klaus ^c   Schäuble, Barbara ^b  

^a Epilepsy Centre Kork   (Germany)

^b JANSSEN CILAG GMBH   (Germany)

^c GEM   (Germany)

Author keywords

Aberrant Behavior Checklist (ABC); Behavior; Epilepsy; Intellectual disability; Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER) scale; Seizure; Topiramate

Indexed keywords

BARBEXACLONE; CARBAMAZEPINE; CITALOPRAM; CLOBAZAM; CLONAZEPAM; CLOZAPINE; ETIRACETAM; FELBAMATE; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROMETHAZINE; RISPERIDONE; SULTIAME; TOPIRAMATE; TRIMIPRAMINE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE OF SIDE EFFECTS; ADAPTIVE BEHAVIOR; ADD ON THERAPY; ADOLESCENT; ADULT; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; BEHAVIOR CHANGE; CEREBRAL PALSY; CLINICAL ARTICLE; CONTROLLED STUDY; CONTUSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EAR DISEASE; EAR INFECTION; EDEMA; FATIGUE; FEMALE; FOCAL EPILEPSY; FRACTURE; GASTROINTESTINAL DISEASE; GENERALIZED EPILEPSY; HAIR LOSS; HUMAN; INJURY; INTELLECTUAL IMPAIRMENT; INTERPERSONAL COMMUNICATION; LACERATION; MALE; MEDICAL ASSESSMENT; MENTAL DEFICIENCY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NERVOUSNESS; NOSE INFECTION; PHARYNGITIS; PSYCHOMOTOR DISORDER; RATING SCALE; RECOMMENDED DRUG DOSE; RESTLESSNESS; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOCIAL ADAPTATION; SOCIAL BEHAVIOR; SPEECH DISORDER; SUDDEN DEATH; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANTICONVULSANTS; BEHAVIOR; CEREBRAL PALSY; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SEIZURES; SOCIAL BEHAVIOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63249128451     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.12.017     Document Type: Article

References (25)

1. Pellock J.M., and Morton L.D. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev 6 (2000) 309-323
2. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
3. Coppola G., Caliendo G., Veggiotti P., et al. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res 51 (2002) 147-153
4. Guerreiro MM, Manreza ML, Scotoni AE, et al. A pilot study of topiramate in children with Lennox-Gastaut syndrome. Arq Neuropsiquiatr 1999;57(2A):167-75.
5. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC, for the Topiramate YL Study Group. Topiramate in Lennox-Gastaut syndrome. open-label treatment of patients completing a randomized controlled trial. Epilepsia 2000;41(Suppl. 1):S86-90.
6. Glauser T.A., Clark P.O., and McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 41 Suppl. 1 (2000) S91-S94
7. Glauser T.A., Clark P.O., and Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 39 (1998) 1324-1328
8. Korinthenberg R., and Schreiner A. Topiramate in children with West syndrome: a retrospective multicenter evaluation of 100 patients. J Child Neurol 22 (2007) 302-306
9. Stefan H., Hubbertz L., Peglau I., et al. Epilepsy outcomes in elderly treated with topiramate. Acta Neurol Scand 118 (2008) 164-174
10. Runge U., Schauble B., Rettig K., and Schreiner A. Topiramat: initiale monotherapie bei älteren patienten mit epilepsie. Aktuel Neurol 34 (2007) 272-275
11. Kowalik A., Rimpau W., Adam H., et al. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy. Acta Neurol Scand 117 (2008) 159-166
12. Kerr M.P., Baker G.A., and Brodie M.J. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy Behav 7 (2005) 472-480
13. Kanner A.M., Wuu J., Faught E., Tatum W.O., Fix A., and French J.A. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4 (2003) 548-552
14. Reith D., Burke C., Appleton D.B., Wallace G., and Pelekanos J. Tolerability of topiramate in children and adolescents. J Paediatr Child Health 39 (2003) 416-419
15. Jose R.J., Cairns A., and Babbs C. Topiramate-induced psychosis in two members of the one family: a case report. J Med Case Rep 2 (2008) 195
16. Mula M., Trimble M.R., and Sander J.W. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 48 (2007) 2322-2326
17. Teive H.A., Arruda W.O., Munhoz R.P., and Werneck L.C. Topiramate-induced psychosis: report of two cases. Expert Opin Drug Saf 5 (2006) 741-742
18. Besag F.M. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 3 (2004) 1-8
19. Matson J.L., and Boisjoli J.A. Cutoff scores for the Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER) for adults with intellectual disability. Behav Modif 32 (2008) 109-120
20. Matson J.L., Leblanc L.A., and Weinheimer B. Reliability of the Matson evaluation of social skills in individuals with severe retardation (MESSIER). Behav Modif 23 (1999) 647-661
21. Matson J.L., Carlisle C.B., and Bamburg J.W. The convergent validity of the Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER). Res Dev Disabil 19 (1998) 493-500
22. Paclawskyj T.R., Rush K.S., Matson J.L., and Cherry K.E. Factor structure of the Matson Evaluation of Social Skills for Individuals with Severe Retardation (MESSIER). Br J Clin Psychol 38 Pt. 3 (1999) 289-293
23. Rojahn J., Aman M.G., Matson J.L., and Mayville E. The Aberrant Behavior Checklist and the behavior problems inventory: convergent and divergent validity. Res Dev Disabil 24 (2003) 391-404
24. Arvio M., and Sillanpaa M. Topiramate in long-term treatment of epilepsy in the intellectually disabled. J Intellect Disabil Res 49 Pt. 3 (2005) 183-189
25. Lathers C.M., and Schrader P.L. Clinical pharmacology: drugs as a benefit and/or risk in sudden unexpected death in epilepsy?. J Clin Pharmacol 42 (2002) 123-136